JP2018536428A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018536428A5 JP2018536428A5 JP2018530548A JP2018530548A JP2018536428A5 JP 2018536428 A5 JP2018536428 A5 JP 2018536428A5 JP 2018530548 A JP2018530548 A JP 2018530548A JP 2018530548 A JP2018530548 A JP 2018530548A JP 2018536428 A5 JP2018536428 A5 JP 2018536428A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- rsv
- recombinant rsv
- nucleotide
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 128
- 239000002773 nucleotide Substances 0.000 claims description 104
- 125000003729 nucleotide group Chemical group 0.000 claims description 104
- 230000035772 mutation Effects 0.000 claims description 54
- 238000012986 modification Methods 0.000 claims description 40
- 230000004048 modification Effects 0.000 claims description 40
- 230000037430 deletion Effects 0.000 claims description 28
- 238000012217 deletion Methods 0.000 claims description 28
- 238000006467 substitution reaction Methods 0.000 claims description 22
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims description 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 9
- 108091006027 G proteins Proteins 0.000 claims description 8
- 108091000058 GTP-Binding Proteins 0.000 claims description 8
- 230000002238 attenuated effect Effects 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 230000004075 alteration Effects 0.000 claims description 7
- 230000028993 immune response Effects 0.000 claims description 7
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 claims description 6
- 102000030782 GTP binding Human genes 0.000 claims description 6
- 101710141454 Nucleoprotein Proteins 0.000 claims description 6
- 108091033319 polynucleotide Proteins 0.000 claims description 6
- 102000040430 polynucleotide Human genes 0.000 claims description 6
- 239000002157 polynucleotide Substances 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 108020004705 Codon Proteins 0.000 claims description 4
- 238000004113 cell culture Methods 0.000 claims description 4
- 102220226361 rs1064794680 Human genes 0.000 claims description 4
- 102220059225 rs748406142 Human genes 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000002299 complementary DNA Substances 0.000 claims description 2
- 230000002163 immunogen Effects 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000002458 infectious effect Effects 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007923 nasal drop Substances 0.000 claims description 2
- 229940100662 nasal drops Drugs 0.000 claims description 2
- 239000007922 nasal spray Substances 0.000 claims description 2
- 229940097496 nasal spray Drugs 0.000 claims description 2
- 230000001681 protective effect Effects 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 102220082314 rs863224177 Human genes 0.000 claims description 2
- 230000029812 viral genome replication Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022030778A JP7357709B2 (ja) | 2015-12-11 | 2022-03-01 | さまざまな弱毒化表現型をもたらすｍ２－２ ｏｒｆにおける突然変異を含む組換えｒｓウイルス株 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562266199P | 2015-12-11 | 2015-12-11 | |
| US62/266,199 | 2015-12-11 | ||
| PCT/US2016/066146 WO2017100759A1 (en) | 2015-12-11 | 2016-12-12 | Recombinant respiratory syncytial virus strains with mutations in the m2-2 orf providing a range of attenuation phenotypes |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022030778A Division JP7357709B2 (ja) | 2015-12-11 | 2022-03-01 | さまざまな弱毒化表現型をもたらすｍ２－２ ｏｒｆにおける突然変異を含む組換えｒｓウイルス株 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018536428A JP2018536428A (ja) | 2018-12-13 |
| JP2018536428A5 true JP2018536428A5 (enExample) | 2020-01-23 |
| JP7079197B2 JP7079197B2 (ja) | 2022-06-01 |
Family
ID=57714677
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018530548A Active JP7079197B2 (ja) | 2015-12-11 | 2016-12-12 | さまざまな弱毒化表現型をもたらすｍ２－２ ｏｒｆにおける突然変異を含む組換えｒｓウイルス株 |
| JP2022030778A Active JP7357709B2 (ja) | 2015-12-11 | 2022-03-01 | さまざまな弱毒化表現型をもたらすｍ２－２ ｏｒｆにおける突然変異を含む組換えｒｓウイルス株 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022030778A Active JP7357709B2 (ja) | 2015-12-11 | 2022-03-01 | さまざまな弱毒化表現型をもたらすｍ２－２ ｏｒｆにおける突然変異を含む組換えｒｓウイルス株 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10655109B2 (enExample) |
| EP (1) | EP3386539A1 (enExample) |
| JP (2) | JP7079197B2 (enExample) |
| KR (2) | KR20250134719A (enExample) |
| CN (1) | CN109310752B (enExample) |
| AR (1) | AR106956A1 (enExample) |
| AU (1) | AU2016366771B2 (enExample) |
| BR (1) | BR112018011674A2 (enExample) |
| CA (1) | CA3007408A1 (enExample) |
| WO (1) | WO2017100759A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3630173A1 (en) | 2017-05-29 | 2020-04-08 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Recombinant chimeric bovine/human parainfluenza virus 3 expressing rsv g and its use |
| CA3185143A1 (en) * | 2020-06-05 | 2021-12-09 | Peter Collins | Live attenuated respiratory syncytial virus |
| TW202535439A (zh) | 2023-11-17 | 2025-09-16 | 美商賽諾菲巴斯德公司 | 海藻糖疫苗調配物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3224404A1 (de) | 1982-06-30 | 1984-01-05 | LuK Lamellen und Kupplungsbau GmbH, 7580 Bühl | Reibungskupplung sowie verfahren zu deren montage |
| US7465574B2 (en) | 1994-09-30 | 2008-12-16 | Medimmune, Llc | Recombinant RSV virus expression systems and vaccines |
| US6713066B1 (en) | 1996-07-15 | 2004-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2 |
| CA2230033C (en) | 1995-09-27 | 2010-01-26 | Peter L. Collins | Production of infectious respiratory syncytial virus from cloned nucleotide sequences |
| US20040005542A1 (en) * | 2001-06-22 | 2004-01-08 | Krempl Christine D | Respiratory syncytial virus vaccines expressing protective antigens from promotor- proximal genes |
| CA2797703A1 (en) | 2000-11-28 | 2002-06-06 | Medimmune, Llc | Recombinant rsv virus expression systems and vaccines |
| DE10118446A1 (de) | 2001-04-12 | 2002-10-17 | Thomas Hartung | Prüfverfahren zur Untersuchung fließfähiger Medien auf Gehalte an mikrobiellen Toxinen |
| EP3511015B9 (en) | 2012-04-13 | 2025-10-22 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Genetically stable live attenuated respiratory syncytial virus vaccine and its production |
| US20160228536A1 (en) * | 2013-09-18 | 2016-08-11 | Medimmune, Llc | Recombinant respiratory syncytial virus (rsv) and vaccines |
| WO2017030997A1 (en) | 2015-08-14 | 2017-02-23 | Research Institute At Nationwide Children's Hospital | Respiratory syncytial virus having altered ns1 protein function and related materials and methods |
-
2016
- 2016-12-12 BR BR112018011674-2A patent/BR112018011674A2/pt active Search and Examination
- 2016-12-12 AU AU2016366771A patent/AU2016366771B2/en active Active
- 2016-12-12 CA CA3007408A patent/CA3007408A1/en active Pending
- 2016-12-12 CN CN201680081646.4A patent/CN109310752B/zh active Active
- 2016-12-12 AR ARP160103793A patent/AR106956A1/es unknown
- 2016-12-12 US US16/061,314 patent/US10655109B2/en active Active
- 2016-12-12 KR KR1020257029082A patent/KR20250134719A/ko active Pending
- 2016-12-12 JP JP2018530548A patent/JP7079197B2/ja active Active
- 2016-12-12 WO PCT/US2016/066146 patent/WO2017100759A1/en not_active Ceased
- 2016-12-12 EP EP16822321.2A patent/EP3386539A1/en active Pending
- 2016-12-12 KR KR1020187019759A patent/KR102854980B1/ko active Active
-
2020
- 2020-05-18 US US16/877,277 patent/US11332721B2/en active Active
-
2022
- 2022-03-01 JP JP2022030778A patent/JP7357709B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nagai | Paramyxovirus replication and pathogenesis. Reverse genetics transforms understanding | |
| US8097459B2 (en) | Methods and compositions for increasing replication capacity of an influenza virus | |
| Nagai et al. | Paramyxovirus reverse genetics is coming of age | |
| JP2006524511A5 (enExample) | ||
| HU229101B1 (en) | Dna transfection system for the generation of infectious influenza virus | |
| JP2009540801A5 (enExample) | ||
| CN105518129B (zh) | 减毒流感疫苗和其用途 | |
| EP2970981B1 (en) | Recombinant rsv with silent mutations, vaccines, and methods related thereto | |
| Smith et al. | Variation in influenza virus genes: epidemiological, pathogenic, and evolutionary consequences | |
| CN101952427A (zh) | 产生流感病毒粒子的线性表达构建体 | |
| JP2008507298A5 (enExample) | ||
| RU2011122615A (ru) | Живой аттенуированный респираторно-синцитиальный вирус | |
| Kawano et al. | Sequence determination of the hemagglutinin-neuraminidase (HN) gene of human parainfluenza type 2 virus and the construction of a phylogenetic tree for HN proteins of all the paramyxoviruses that are infectious to humans | |
| JP2019534709A (ja) | 弱毒化表現型を有するヒト呼吸器多核体ウイルス（ｒｓｖ）のためのワクチン候補 | |
| JP2019534709A5 (enExample) | ||
| JP2018536428A5 (enExample) | ||
| Barik et al. | Nucleotide sequence analysis of the L gene of vesicular stomatitis virus (New Jersey serotype): identification of conserved domains in L proteins of nonsegmented negative-strand RNA viruses | |
| TWI396741B (zh) | 非洲綠猴腎細胞培養之流感病毒及疫苗 | |
| JP2019505567A5 (enExample) | ||
| Skiadopoulos et al. | Determinants of the host range restriction of replication of bovine parainfluenza virus type 3 in rhesus monkeys are polygenic | |
| JP2005508158A5 (enExample) | ||
| CN105131124A (zh) | 新的融合蛋白及其用于制备针对丙型肝炎的疫苗的用途 | |
| JP2020522249A5 (enExample) | ||
| JP2018533908A5 (enExample) | ||
| CN103316357B (zh) | 携带rsv基因的重组流感病毒嵌合疫苗及其制备方法 |